Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

Future-shaping trend: Cancer screening programs  

Consistent precise cancer imaging can have a high impact on therapeutic outcomes. We help you to provide high quality cancer care with enhanced clinical performance by harnessing the broadest portfolio of imaging solutions. 

One major challenge in cancer care is late diagnosis. Late diagnosis can lead to fewer treatment options, with minimally invasive choices no longer possible. 

But this scenario is changing. Lung cancer screening offers an excellent example of how screening can impact approaches to treatment: 

“The recent results from the I-ELCAP study, which looked at treatment outcomes for high-risk persons over 20 years, whose cancer was identified at an early stage, showed a lung cancer specific survival rate of 80 percent.1 Contrast that with the fact that, with later-stage lung cancer, the treatment goal is often palliative rather than curative,” explains Dr. Sebastian Schmidt, Head of Strategy, Innovation and Medical Affairs CT at Siemens Healthineers. 

This requires the ability to provide screening with high sensitivity while still maintaining the lowest possible dose, combined with the capability to treat patients with minimally invasive options. Our CT portfolio delivers low or ultra-low dose CT scans for cancer patients, which can get as low as standard X-ray dose levels while maintaining their diagnostic quality.2

 

1
2